As adequately powered phase 3 trials investigating various incretin agonists in MASLD and MASH with robust histological endpoints are still underway, current practice guidelines highlight the beneficial effects of treatment with GLP-1 agonists on non-liver related endpoints and for other comorbidities, such as diabetes or obesity, without generally endorsing this class of agents for the specific treatment of MASLD/MASH yet [31, 32]. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.